Clinical Trial Detail

NCT ID NCT03122522
Title A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

melanoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.